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This study investigated the humoral immunization of Astragalus polysaccharide (APS) against H9N2 avian influenza
virus (H9N2 AIV) infection in chickens.
The effects of APS treatment on H9N2 infection was evaluated by an MTT [3(4, 5-dimethylthiazol-2-yl)-2, 3-diphenyl
tetrazolium bromide] assay and analysis of MHC and cytokine mRNA expression. The effect on lymphocyte and
serum antibody titers in vivo was also investigated. IL-4, IL-6, IL-10, LITAF, IL-12 and antibody titers to H9N2 AIV were
enhanced in the first week after APS treatment. The results indicated that APS treatment reduces H9N2 AIV
replication and promotes early humoral immune responses in young chickens.
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Avian influenza (AI) is a highly contagious disease which
causes acute illness, often culminating in death, in domestic
poultry and other animals. The high morbidity and mortal-
ity associated with this pathogen have an impact on both
economic and societal costs. Migratory birds, mechanical
vectors (such as contaminated cages and clothing), and the
international trade in live poultry, contribute to the spread
of infection. The disease can be transmitted to humans
through exposure to infected birds or the handling of
infected carcasses [1]. The disease has wide occurrence and
the virus has the potential to mutate to a highly pathogenic
form with the potential for zoonotic transmission. AI sub-
type H9N2 belongs to the low pathogenic avian influenza
virus (AIV) group; considered to be a common cause of
disease epidemics [2,3]. H9N2 infections in chickens are as-
sociated with low mortality rates, mild respiratory infec-
tions, reduced performances in egg production (particularly
for the local poultry industry), and co-infections with
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reproduction in any medium, provided the oror attenuated vaccine strains which exacerbate the disease
[2]. Currently, vaccination is one of the most promising
control measures for H9N2 AIV. Unvaccinated chickens
can become infected with modified live H9N2 virus strains
used for early immunization [4], while inactivated vaccines
have been shown to be safe and efficacious against H9N2
AIV [5]. Novel immune adjuvants are still in development
and their use is highly desirable for producing vaccines
which evoke a rapid immune response against viruses.
Compositional analysis by gas chromatography revealed
that Chinese herbal polysaccharides such as Astragalus
[Huang qi] contain mannose, D-glucose, D-galactose, xy-
lose and L-arabinose. These polysaccharides are used as an
immunomodulating agent in mixed herbal decoctions to
treat common colds, diarrhea, fatigue, and anorexia [6].
In China, APS is widely used as an immune adjuvant;
having been identified as a class of macromolecule that can
profoundly affect the immune system, stimulate cell prolif-
eration, induce the expression of surface antigens on lym-
phocytes, affect the expression of cytokines, and promote
the production of antibodies [7]. In a previous study, it was
reported that APS possess effective immunostimulatory ef-
fects when used in vaccination programs against Foot and
mouth disease virus (FMDV), Newcastle disease virus
(NDV) and Infectious bursal disease virus (IBDV) [5,8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pression of MHC class II, CD40, and CD86, and improve
FMDV antigen-presentation during the early stages of the
immune response [8].
In this research, the appropriate concentration and anti-
viral action of APS on the propagation of H9N2 AIV in
chick embryo fibroblasts (CEF) was investigated. We also
studied how APS affected mRNA expression of IL-2, IL-4,
IL-6, IL-10, LITAF and IL-12 in CEF. The variation in per-
ipheral blood lymphocytes in chickens before and after
immunization, and in antibody titer, were also investigated
to assess the immunoregulatory effect of APS on chickens
at pre-vaccination, and to evaluate the immunization
potential of Astragalus polysaccharide (APS) against
H9N2 AVI.Materials and methods
Preparation of H9N2 avian influenza virus and cell culture
Ten-day-old embryonating specific-pathogen-free (SPF)
chicken eggs (Guangdong Dahuanong Animal Health
Products Co. Ltd, Guangzhou, China) were inoculated
with H9N2 virus (0.2mL/egg). Infected allantoic fluids
were harvested 48h post-inoculation and concentrated
with a 100K tangential flow filtration capsule (Pall Life
Sciences) by centrifugation at 40,000rpm for 1h. The
suspension was loaded onto a 30 to 60% (wt/wt) sucrose
gradient and subjected to centrifugation at 26,000rpm at
4°C with a SW-40 Ti rotor (Beckman Instruments, Palo
Alto, CA) for 3h using the slowest acceleration and
braking rates. The viral pellets were washed and
centrifuged at 40,000rpm for 1h at 4°C. Subsequently,
the pellets were re-dissolved in 1mL of PBS, filtered
through a 0.22 Millipore filter, and stored at −70°C [9].
CEF cultures were prepared from 10-day-old chicken
embryos according to standard protocols [10,11].
Dulbecco’s Modified Eagle Medium (DMEM; Gibco-
Invitrogen) was used as the growth medium. In brief,
embryo tissue was cut into pieces and diluted to 1 × 106
cells/mL Following filtration the cells were cultivated in
a 5% CO2 incubator at 37°C for 48h.Extraction and purification of APS
Powder ground APS obtained from South China Agri-
cultural University (Guangzhou, China) was boiled in
distilled water for 4h at 100°C. After filtration to remove
debris, the filtrate was concentrated in a rotary evapor-
ator. Protein was removed using the Savage method
[12]. Crude polysaccharide fractions were obtained by
precipitation with three volumes of ethanol and desicca-
tion in vacuo. The precipitate was re-dissolved in dis-
tilled water and loaded on a D101 macro-porous resin
column (2.6cm × 60cm) to remove pigment. The effluent
was collected and the polysaccharide fractions werequantitatively determined using a phenol-sulfuric acid
assay [13] with glucose as the reference standard.
Determination of safety concentration of APS to CEF
The CEF safety concentration was determined as reported
by Huang et al. [14]. In brief, CEF monolayers in 96-well
plates were exposed to Astragalus polysaccharide at a series
of concentrations; conducted in replicates of four wells per
concentration. After culturing for 72h at 38.5°C in a hu-
midified atmosphere of 5% CO2, the supernatant was re-
moved and 100μL Dimethyl sulfoxide (DMSO; Sigma,
Kent, UK) added. The plates were shaken for 5min to en-
sure complete dissolution of the crystals. The absorbance at
570nm (A570) for each well was measured by a microtiter
enzyme-linked immunosorbent assay reader (Model DG-
3022, East China Vacuum Tube Manufacturer). The A570
value correlates to the number of live cells; the higher the
value at A570 the greater the number of viable cells. The
A570 values for APS treated CEFs were higher than for the
corresponding cells of the control group. These results indi-
cated that the polysaccharide was not cytotoxic to CEFs at
the concentrations used. The corresponding concentrations
of APS were considered as the maximum safety concentra-
tion for CEF.
Determination of optimal APS concentration for CEF
growth
CEF confluent monolayers, prepared in sextuplicate in 96-
well culture plates, were overlaid with serial doubling dilu-
tions of APS in DMEM (2,500 to 4.833μg/mL), and cul-
tured at 37°C in a humidified 5% CO2 incubator for 8h.
The effect of APS concentration on CEF viability was
determined by the MTT 3-(4,5-Dimethyithiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) assay. Briefly, the media was
discarded, 20μL of MTT (Amresco Solon, OH; 5 ìg/mL)
added to each well, and the plates incubated at 37°C in a
humidified atmosphere of 5% CO2 for 4h. At the comple-
tion of the incubation, 10μL DMSO (Sigma) was added
and the plates incubated at 37°C for 5min to ensure
complete dissolution of the formazan crystals. Absorbance
was measured at A570 using a microtiter ELISA reader
(Molecular Devices Emax, CA, USA).
Antiviral assays
Antiviral activity was evaluated as reported by Huang
et al. [14]. In brief, serial two-fold dilutions of APS and
H9N2 virus were added to monolayers of CEF cultures
under the conditions detailed below.
Pre-addition of APS: APS solutions (100mL/well, four
wells per concentration) were added to CEF monolayers
prior to the addition of virus. Following incubation in
APS for 2h at 38.5°C with 5% CO2, the supernatant was
removed, the cells washed twice with Hanks’ solution,
and the virus added.
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to CEF monolayers prior to the addition of APS. Follow-
ing incubation with H9N2 for 2h at 38.5°C with 5% CO2,
the viral inoculum was removed, the cells washed twice
with Hanks’ solution, and APS solution added; four wells
for each concentration.
Simultaneous addition of APS and H9N2 virus: APS
and virus solutions were pre-incubated together for 4h
at 4°C prior to addition to CEF monolayers; four wells
per concentration.
All plates were cultured at 38.5°C in a 5% CO2 incuba-
tor. When complete cytopathic effect (CPE) was observed
for the H9N2 control group (~ 72h), CEF viability was
measured by MTT assay. The mean cellular A570 values
were an indicator of antiviral activity. When the A570 value
of the APS group was significantly higher than that of the
virus control group, it demonstrated that the correspond-
ing polysaccharide had significant activity.
Animal experiments
One hundred and twenty, five-day-old SPF white male
leghorn avian broilers, purchased from Guangdong
Dahuanong Animal Health products Co. Ltd., were di-
vided into four groups and maintained in four positive
pressure isolators. Experimental groups contained three
sample groups (30 chickens per group) and one control
group (including vaccinated and unvaccinated).
At 7 d post hatch, three sample groups were hypodermic-
ally injected with APS at three different concentrations
(5mg/kg, 10mg/kg and 20mg/kg) once a day for five succes-
sive days. At 12 d post-hatch, six chickens per group were
euthanized by cervical dislocation and their blood immedi-
ately collected. Peripheral blood lymphocytes separated
from the blood samples (5mL per chicken) were used for
flow cytometry and real-time PCR. The immune organs
were weighted for statistical analysis and immediately
stored at −70°C. Simultaneously, nine chickens per group
were challenged with 107.5EID50/0.2mL of H9N2 AIV. Add-
itionally, 15 birds were taken from each group, with the ex-
ception of the control group, and were immunized
subcutaneously with an inactivated oil-emulsion vaccine of
H9N2 avian influenza virus (Guangdong Dahuanong Ani-
mal Health Products Co. Ltd.) at 13 and 20 d post-hatch.
Antibody titers were measured at seven and 14 d post-
immunization. The experimental procedures performed on
chickens at 12 d post-hatch were repeated at 26 d post-
hatch.
Ethics statement
All animal experiments and husbandry involved in this
study, and presented in this manuscript, were conducted in
accordance with the guidelines of the South China Agricul-
tural University Animal Care and Use Committee, which
operates under the Animal Welfare Law and Regulations ofthe Department of Health and Human Services. The South
China Agricultural University Animal Care and Use Com-
mittee approved all details of this study.
Three color flow cytometry
Blood samples were placed in Petri tubes with sodium
heparin and intermixed with an equal volume of Hanks’
balanced salt solution (HBSS, pH 7.2 ~ 7.4). An aliquot
was layered over 5mL LSM (lymphocyte separation
medium) and centrifuged at 2,000rpm for 20min in a
swing-bucket rotor. Peripheral blood lymphocytes were
recovered from the LSM-HBSS interface and washed 3
times with PBS. A total of 2 × 106 lymphocytes inrpmI
1640 medium (Roswell Park Memorial Institute 1640
medium) containing 10% (vol/vol) BSA were incubated
with 20μL anti-chicken CDS-FITC (SouthernBiotech) in
the absence of light for 20min. Cell suspensions were
washed with 500μL PBS, centrifuged at 1,200rpm for
10min, the supernatant discarded and the cells re-
suspended in 500μL PBS [15]. The cells were then ana-
lyzed using a FACSAria flow cytometer (version 6.1; BD
Biosciences).
Measurement of antibody titer
The antibody titer was measured by the hemagglutination
inhibition (HI) test [16]. The HI test was a standard beta
test, using 4 hemagglutinating units of antigen in 96-well
plates, where the test serum had been diluted two-fold. HI
endpoint titers were determined as the reciprocal of the
highest serum dilution that produced complete inhibition
of hemagglutination.
Blood samples (1.0mL/chicken) obtained from the main
brachial vein were drawn into Eppendorf tubes and allowed
to clot at 37°C for 2 h. Serum was separated by centrifuga-
tion and stored at −20°C for HI antibody determination.
Briefly, two-fold serial dilutions (1:2 to 1:2,048) of heat
inactivated (56°C for 30min) serum, was applied to a
96-well, V-shaped bottom microtiter plate containing
50μL/wellcmF-PBS, and 50μL/well H9N2 antigen (4
hemagglutination units); with the exception of the last row
(controls). The antigen: serum mixture was incubated for
10min at 37°C, 50μL of a 1% rooster erythrocyte suspension
added to each well and the plates re-incubated for 30min.
Positive serum, negative serum, erythrocytes, and antigens
were also included as controls. The highest dilution of
serum causing complete inhibition of erythrocyte agglutin-
ation was considered the end point. The geometric mean
titer was expressed as reciprocal log2 values of the highest
dilution that displayed anti-H9N2-HI.
Real-time PCR
Total RNA was extracted from CEF using Trizol reagent
(Takara Biotechnology, Dalian, China) for the detection of
cytokines and H9N2 expression. The quantity of total RNA
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tical density (OD) 260/280 determined to be between 1.8 and
2.0. The isolated RNA was digested with Recombinant
DNase I (Takara Biotechnology, Dalian, China) at 37°C for
30min. Oneμg of total RNA was used for reverse transcrip-
tion with ReverTra Ace® qPCR RT kit (Toyobo; Osaka,
Japan) and amplifications were performed with 1μL cDNA
in a total volume of 20μL SYBR Green Real-time PCR Mas-
ter Mix (Roche; Mortlake, Australia); all reactions were
performed with the Stratagene Mx3005P QPCR system (La
Jolla, Ca) according to the manufacturer’s instruction. All
reactions were completed in triplicate. Relative expression
fold change was calculated by the 2△△Ct method, and
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was
used as the endogenous reference gene to normalize the ex-
pression level of target gene. The primers used in the real-
time PCR assay were listed in Table 1.
Statistical analysis
All data were presented as mean ± SEM. Comparisons be-
tween two groups were analyzed using unpaired Student’s
T- tests. Comparisons among multiple groups were ana-
lyzed by ANOVA followed by post hoc analysis using the
Tukey’s multiple comparison test. All statistical analysis was
conducted using SPSS 17.0 software (SPSS, Chicago, IL,
USA) and P < 0.05 was considered to be statistically signifi-
cant. All experiments were performed at least three times.
Results
Optimal APS concentration and antiviral assays
Determination of the optimal APS concentration and the
results of the antiviral assays are presented in Tables 2 and
3. The optimal APS concentration for the stimulation of
CEF proliferation was determined to be 321.25μg/mL. AnTable 1 Sequences of the oligonucleotide primers used in rea
RNA target Primer se
Sense
MHC class I* 5′-AAGAAGGGGAAGGGCTACAA-3′










MHC = Major histocompatibility complex.
GAPDH = glyceraldehyde-3-phosphate-dehydrogenase.increase in CEF proliferation was observed for all APS con-
centrations studied (4.833 to 2,500μg/mL).
On pre-treatment of CEF with APS, the A570 values for
the seven concentrations (4.833 to 321.25μg/mL) were sig-
nificantly (P < 0.05) greater than was observed for the cor-
responding controls. These results suggest that at these
concentrations of APS, CEF proliferation was enhanced,
with the greatest degree of proliferation achieved at an APS
concentration of 321.25μg/mL. The A570 values for both
APS and the pre-addition of APS were significantly (P <
0.05) higher than for the corresponding virus controls,
which indicated that virus activity was inhibited at all APS
and pre-addition APS concentrations. In contrast, a num-
ber of the A570 values for post-addition and simultaneous
addition of APS were less than for the virus controls
suggesting that at such concentrations viral activity was not
inhibited (Tables 2 and 3). For the pre-addition of APS the
relative expressions of H9N2 virus at various APS concen-
trations, particularly 321.25μg/mL, were significantly low.
The proliferation of H9N2 was approximately four times
lower for the pre-addition APS concentration of 321.25μg/
mL when compared with 2,500μg/mL and 4.833μg/mL
(Figure 1).
Major histocompatibility complex and cytokine
expression in CEF cells
The relative expression levels for cytokines IL-4, IL-10,
LITAF and IL-12 were high, in particular for IL-12, fol-
lowing APS treatment. Following challenge with H9N2
virus the relative expressions of IL-4 and IL-10 were also
considerably high, but the expression of IFN-γ, LITAF,
IL-6 and IL-12 were down regulated. MHC I and MHC
II expression wasminimal following APS treatment but

















Table 2 The A570 values of the optimal APS concentration and antiviral assays (25006μg/mL −156.6μg/mL)
Groups
Groups
2,500μg/mL 1,250μg/mL 625μg/mL 321.25μg/mL 156.6μg/mL
APS 0.281 ± 0.026abcd* 0.303 ± 0.0061abc* 0.304 ± 0.019abc* 0.314 ± 0.017ab* 0.308 ± 0.017abc*
Pre-add APS 0.237 ± 0.003a* 0.238 ± 0.004a* 0.241 ± 0.012a* 0.269 ± 0.016b* 0.266 ± 0.006ab*
Post-add APS 0.205 ± 0.011abc 0.204 ± 0.004bd 0.198 ± 0.006de 0.190 ± 0.004de 0.178 ± 0.013de
Sim-add APS 0.166 ± 0.004a 0.174 ± 0.005a 0.181 ± 0.002ab 0.182 ± 0.004abcd 0.183 ± 0.007be
Virus Control 0.175 ± 0.007
Cell Control 0.242 ± 0.002*
a-f data within row without the same superscripts differ significantly (P < 0.05). *Data differed significantly (P < 0.05) when compared with virus control.
APS = Astragalus polysaccharide.
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The proportion of lymphocytes expressing CD3+, CD4+,
and CD8+ T cell surface markers are presented in
Figures 4, 5 and 6. Prior to immunization, the number
of CD3+ and CD8+ lymphocytes were lower for the APS
treatment groups (5mg/kg and 10mg/kg), compared with
the controls. However, following immunization CD3+
and CD8+ T cell populations increased for the APS
treatment groups but decreased for the non-APS treat-
ment groups (Figures 4 and 6). The numbers of CD4+
lymphocytes in the 20mg/kg APS treatment group were
higher than for all other groups, both pre- and post-
immunization (Figure 5).
Antibody levels
Antibody levels for the APS treatment groups were sig-
nificantly (P < 0.05) increased, and at a greater rate, than
was observed for the untreated group (no APS) seven
days post-challenge with H9N2 virus (Figure 7A). Four-
teen days post-challenge no difference in antibody titers
was observed between the 20mg/kg APS and H9N2
groups (Figure 7B). At seven days post-immunization
with inactive vaccine the antibody titers of the APS
groups (5mg/kg and 10mg/kg) were significantly (P <
0.05) higher than for the untreated groups (Figure 8A).
However, at 14 d post-immunization with the inactive
vaccine there was no difference in antibody titers be-
tween APS treated groups (10mg/kg and 20mg/kg) andTable 3 The A570 values of the optimal APS concentration and
Groups
78.21μg/mL 39.09μg/mL
APS 0.289 ± 0.0081abcd* 0.281 ± 0.007abcde*
Pre-add APS 0.254 ± 0.012ab* 0.249 ± 0.005ab*
Post-add APS 0.189 ± 0.008e 0.181 ± 0.006de
Sim-add APS 0.189 ± 0.006abcd 0.180 ± 0.004abcd
Virus Control 0.175 ± 0.007
Cell Control 0.242 ± 0.002*
a-f data within row without the same superscripts differ significantly (P <0.05). *Data
APS = Astragalus polysaccharide.the vaccine group (Figure 8B). The 5mg/kg APS group
attained the highest antibody titer at 7 and 14 d post-
immunization with inactive vaccine (Figures 8A and 8B).
Discussion
The experimental results revealed the range of optimum
APS concentrations for use in studies with chick embryo
fibroblasts (CEF). The A570 value is an index reflecting
the number of living cells, cell growth, and polysacchar-
ide inhibition of virus infection [17]. Higher CEF prolif-
eration was observed in the presence of 321.25μg/mL
APS, compared with control groups. Based on these ob-
servations and the practicability of APS administration
all subsequent in vitro experiments were carried out
using 4.833, 321.25 and 2,500μg/mL APS. The optimum
concentration for APS treatment of CEF was established
as 321.25μg/mL. Cell proliferation was enhanced in the
presence of 321.25μg/mL APS (compared with the con-
trol group), and the cell viability of H9N2 virus infected
cells was greater at this concentration of APS than for
the other concentrations investigated. When APS was
pre-added to cultures of CEF, the A570 values for groups
within the range 4.833 to 2,500μg/mL APS were signifi-
cantly higher than for the corresponding virus control
group; indicative that APS could prevent H9N2 infection
at the concentrations studied. During the simultaneous
addition of pre-mixed polysaccharide with virus, the
A570 values of APS for five concentration groups wereantiviral assays (78.216 and 4.83μg/mL)
APS concentration
19.31μg/mL 9.266μg/mL 4.83μg/mL
0.265 ± 0.005df* 0.264 ± 0.002cf* 0.243 ± 0.007ef*
0.252 ± 0.006ab* 0.246 ± 0.001ab* 0.249 ± 0.002ab*
0.176 ± 0.007abd 0.177 ± 0.006abc 0.155 ± 0.008ac
0.171 ± 0.003def 0.162 ± 0.004df 0.161 ± 0.005f
differed significantly (P < 0.05) when compared with virus control.
Figure 1 Illustrates the relative expression of H9N2 virus in CEF at various APS concentrations for the pre-addition APS group. The
inhibition efficiency of APS was more significant at 321.23μg/mL than for 2,500 and 4.833μg/mL.
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trol groups, which indicated that under these conditions
APS could also inhibit H9N2 infection. Following the
post-addition of polysaccharide, the A750 values for
seven APS concentration groups were significantly larger
than that of the virus control group; indicative that they
too could inhibit H9N2 infection under these conditions
(Tables 2 and 3). These results confirmed that when ad-
ministered at an appropriate dosage, APS had significant
antiviral properties, and that the mode of application
could enhance the antiviral activity of APS. The real-
time PCR results showed that the proliferation of H9N2
virus in CEF was lower for three concentrations in the
pre-addition of APS groups, and in particular virus pro-
liferation was significantly low at an APS concentration
of 321.25μg/mL (Figure 1). These results demonstrate
that APS can protect CEF cells against H9N2 virus
infection.
CD3+ and CD4+ are important T lymphocyte
markers. CD + T lymphocytes are primarily responsible
for mediating cytotoxic effects, and the main function of
CD4+ T lymphocytes is the secretion of cell factors























Figure 2 Illustrates the real-time quantitative PCR analysis of major h
IL-4, IL-10, IFN-γ, LITAF, IL-6 and IL-12 in Astragalus polysaccharide-tr
LITAF and IL-12 were higher in the Astragalus polysaccharide treatment group
expression level.the current study, CD3+ and CD8+ levels increased
post- immunization for the APS treated groups, but de-
creased for the untreated (No APS) groups. Prior to
immunization CD4+ lymphocyte populations in the APS
treatment groups (5 and 20mg/kg) were greater than for
the untreated control (No APS). At both pre- and post-
immunization the levels of CD4+ for the 20mg/kg APS
treated group was higher than for all other groups; while
CD4+ levels for the 5mg/kg APS treatment group in-
creased post-immunization.
In the current study, MHC class I and II were poorly
expressed following APS inoculation, but increased upon
challenge with H9N2 virus. MHC molecules are respon-
sible for binding to degraded peptides of invading patho-
gens, their subsequent presentation on the surface of the
infected cell for T cell (Th and cytotoxic T cell) recogni-
tion, and ultimately for the ensuing destruction of the
infected cell. MHC II molecules interact predominantly
with CD4+ helper T cells (Th), while MHC I molecules
interact with CD8+ cytotoxic (killer) T cells. Helper T
cells help to trigger an appropriate adaptive immune re-
sponse. The T cell response is described by the total T





istocompatibility complexes (MHC) I, MHC II, and cytokines IL-2,
eated chicken embryo fibroblasts. Expression levels of IL-2, IL-4, IL-10,
























Figure 3 Illustrates real-time quantitative PCR analysis of major histocompatibility complexes (MHC) I, MHC II, and cytokines IL-2, IL-4,
IL-10, IFN-γ, LITAF, IL-6, and IL-12 in Astragalus polysaccharide-treated chick embryo fibroblasts (CEF) infected with H9N2 AIV. IL-4 and
IL-10 were expressed to high levels for CEF treated with 321.25μg/mL APS.
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presented by MHC class I molecules and activates CD8+
cytotoxic lymphocytes (CTL); while exogenous antigen
is presented by MHC II molecules, activating antibody
secreting B cells and helper CD4 + T cells [20]. Following
H9N2 infection, increased levels of MHC class I and II
were detected in APS treatment groups, when compared
with untreated (No APS) groups. Similarly, the percent-
age of CD3+ and CD8+ was increased; coincident with
the up-regulation of IL-4 and IL-10 expression. These
observations suggest that APS boosts both T cells and B
cells. IL-2 and IFN-γ are secreted by Th1 cells and pro-
mote cell-mediated immunity [21], whereas IL-2, IL-4,
and IL-10 are produced by Th2 cells, and activate B lym-
phocytes resulting in the up regulation of antibody pro-
duction [21,22]. IL-12 plays an important role in the
activities of natural killer (NK) cells, and T-lymphocytes
and mediates the enhancement of the cytotoxic activity
of NK cells and CD8+ cytotoxic T lymphocytes. It is in-
volved in the differentiation of naïve T cells into Th1
cells. It is known as a T cell-stimulating factor, whichFigure 4 Illustrates the percentages of CD3+ lymphocyte expression
was no difference in the percentile level of CD3+ for APS treatment group
APS groups was higher than for the corresponding controls.can stimulate the growth and function of T cells [23]. It
stimulates the production of interferon-gamer (IFN-γ)
and tumor necrosis factor-alpha (TNF-α) from T and
natural killer (NK) cells, and reduces IL-4 mediated sup-
pression of IFN-γ.
The immune system, as a complex network designed,
protects the host from both external (such as bacteria
and viruses) and internal threats (such as malignant
transformation). Cytokines are important mediators of
immune responses. (Role of cytokines in the immune
system). The levels of IL-2, IL-4, IL-10 and LITAF ex-
pression in APS treatment groups was greater than for
the control group; suggesting that APS most probably
stimulated cytokine production through B lymphocyte
and macrophage activation. Some linear antigens, not
readily degraded in the body, and which had an appro-
priately spaced, highly repeated antigenicity such as the
pneumococcal polysaccharide, may stimulate B cells dir-
ectly; independent of thymus and T cell involvement
[24]. Evidence suggests that APS may also be another
example of a linear antigen; persisting for long periodsbefore and after immunization in vivo. Prior to immunization there
s and control groups. After immunization the CD3+ percentage for the
Figure 5 Illustrates the percentages of CD4 + T cell lymphocyte expression before and after immunization in vivo. CD4+ expression was
greatest for the 20mg/kg APS group, both before and after immunization. CD4+ expression increased post immunization for the 5mg/kg
APS group.
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subcapsular sinus of the lymph nodes and the splenic
marginal zone. Individual cytokines often have multiple
effects, the results of which are dependent on their tar-
get cell. The variation of cytokines in our study coin-
cided with the work of Shao et al. [25].
Other studies have confirmed that (expression/produc-
tion?) of LPS-Induced TNF-alpha Factor (LITAF) was
increased after APS inoculation, that it was secreted by
B cells, and could activate macrophages and stimulate
Th1 cells [22]. LITAF was chosen for inclusion in the
current study because it was known to be derived from
monocytes/macrophages and exerted potent cytotoxicity
on tumorigenic cells [26]. It was previously shown that
Astragalus could exert its anti-tumor effect on a variety
of tumors in vivo, and that APS treatment could stimu-
late immune activities in rats with stomach cancer. The
up-regulation of LITAF suggested that APS couldFigure 6 Illustrates the percentages of CD8 + T cell lymphocyte expre
the 5mg/kg APS group was significantly lower prior to immunization, but iprevent the formation of tumors in healthy bodies, while
the down regulation of IFN-γ and LITAF suggested that
the inflammatory activity was mediated.
In the present study, the expression levels of IL-2, IL-4,
and IL-10 for APS treated groups was found to be
markedly higher than for the control group after APS in-
oculation. Higher levels of IL-4 and IL-10 were produced
pre- and post-challenge with H9N2 virus, suggesting that
IL-4 and IL-10 induce long term immunity against H9N2
AIV infection (Figure 2 and 3). In this regard, APS most
probably activated a network of interactions involving a
number of different cytokines.
The humoral response is mediated by the secretion of
antibodies by B lymphocytes, and antibody titer is a
measure of the specific humoral immune response in
chickens following vaccination [27]. In the current study,
higher antibody titers were observed for the APS treated
groups (particularly for the 5 and 10mg/kg groups)ssion before and after immunization in vivo. CD8+ expression for
ncreased to levels higher than all the other groups post-immunization.
Figure 7 Antibody titers of chickens at 7 and 14 d post H9N2 AVI infection for different Astragalus polysaccharide concentrations.
Antibody titers were greatest for chickens in the 5mg/kg group at seven days post H9N2 infection.
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http://www.jasbsci.com/content/4/1/22on d 7 and 14 following either H9N2 AIV infection or
immunization with inactive vaccine. The results pro-
vided evidence that APS could enhance the humoral im-
mune response in chickens, and that the 5 and 10mg/kg
APS treatment groups were more effective in enhancing
the immune response than the 20mg/kg APS treatment
group. This observation corresponds with the work of Li
et al. [27] who reported on the effectiveness of Chinese
herbal medicines, including APS, in enhancing immunity
in chickens. The antibody titer for the 5mg/kg APS group
was the highest at 7 and 14 d post-immunization
with the H9N2 inactivated vaccine. Collectively, the re-
sults obtained from this study indicated that theFigure 8 Antibody titers of chickens at 7 and 14 d post-vaccination w
titers were greatest for chickens in the 5mg/kg group at both 7 and 14 d padministration of the appropriate dose of APS could en-
hance antibody production and improve humoral im-
munity, and that APS had the properties of an anti-viral
agent. These observations coincided with that reported
by Kong et al. [28].
Conclusions
From this study, the following conclusions were derived:
1. At an appropriate concentration (231.25μg/mL) APS
can drastically reduce the proliferation of H9N2 virus.
2. APS enhanced the proliferation of CEF cells when
used at concentrations > 9.766μg/mL. The exception,ith the H9N2 vaccine for different APS concentrations. Antibody
ost- vaccination with the H9N2 vaccine.
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concentrations of 2,500μg/mL and 1,250μg/mL.
3. APS effectively increases the expression of IL-2, IL-4,
IL-6, IL-10, LITAF and IL-12, promotes cell growth,
and enhances anti-H9N2 activity.
4. APS promoted a rapid humoral response following
H9N2 vaccine immunization or H9N2 AIV
infection.
5. The appropriate dose of APS (5 and 10mg/kg)
significantly enhanced the specific immune response
in chickens, and improved vaccine effectiveness;
promoting an earlier peak that increased rapidly and
was sustained for a longer period of time.
6. The CD4+, CD8+ T lymphocyte content and CD4
+/
CD8
+ values for all the APS treatment groups were
higher than those for the untreated (no APS)
control group. The values for the 5 and 20mg/kg
APS dose groups were significantly higher than the
control group, which indicated that the appropriate
dose of polysaccharide can promote the production
of peripheral CD4+ and CD8+ lymphocytes in
chickens, thereby enhancing cellular immunity.
7. APS inhibited H9N2 both in vitro and in vivo.
The precise mechanisms responsible for the response
to APS require further examination. On the whole, APS
has the potential to diminish disease progression in
H9N2 infected chickens, and its use could provide alter-
native strategies for the control of H9N2 AIV infection.
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